NORTH BRUNSWICK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announces that Ernst & Young LLP (EY US) named Susan L. Levinson, PhD, CEO an Entrepreneur Of The Year® 2021 New Jersey Award finalist. Now in its 35th year, the Entrepreneur Of The Year program honors unstoppable business leaders whose ambition, ingenuity and courage in the face of adversity help catapult us from the now to next and beyond. Dr. Levinson was selected by a panel of independent judges.
“I am honored to have been chosen to be a NJ finalist for this prestigious program to recognize entrepreneurial leaders,” said Dr. Susan Levinson. “It is thanks to our passionate and committed team that BioAegis was able to swiftly and aggressively respond to the COVID-19 challenge, advancing a compelling therapeutic option into Phase 2 in hospitalized COVID patients. We are proud to be a member of the vital NJ biotech ecosystem.”
Dr. Levinson has founded two New Jersey biotech companies in partnership with scientific and business founders and is passionately committed to developing unique products to meet patient needs. The second company, Azure Biotech, is focused on unmet medical needs in women’s health. She is a strong advocate of women in STEM and the biotech ecosystem in NJ. Dr. Levinson was recently elected to the Board of BioNJ, the NJ biotech trade association. She has over 30 years of life sciences pharmaceutical experience spanning the entire value chain, from the lab bench to marketing. Dr. Levinson has a B.S in Biochemistry from University of Wisconsin and a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine.
Entrepreneur Of The Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies. The nominees are evaluated based on six criteria: entrepreneurial leadership; talent management; degree of difficulty; financial performance; societal impact and building a values-based company; and originality, innovation and future plans. Since its launch, the program has expanded to recognize business leaders in more than 145 cities in over 60 countries around the world.
About BioAegis
BioAegis Therapeutics Inc. is a NJ-based clinical stage, private company whose mission is to capitalize on a key component of the body’s innate immune system, gelsolin, to prevent adverse outcomes in diseases driven by inflammation and infection.
BioAegis’ platform is built upon the recombinant form of plasma gelsolin, a highly conserved abundant human protein in healthy individuals. This protein is depleted by a wide range of diseases. Uniquely, this protein controls inflammation without suppressing immunity. Most current anti-inflammatory products, like steroids, work by suppressing immune function, putting patients at risk for subsequent infections and adverse events.
BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women’s Hospital. It holds over 40 patents issued for coverage of infection, inflammatory disease, renal failure, multiple sclerosis and other neurologic diseases. BioAegis will also have US biologics exclusivity and has recently filed new IP in other areas of unmet need.
About Entrepreneur Of The Year®
Entrepreneur Of The Year® is the world’s most prestigious business awards program for unstoppable entrepreneurs. These visionary leaders deliver innovation, growth and prosperity that transform our world. The program engages entrepreneurs with insights and experiences that foster growth. It connects them with their peers to strengthen entrepreneurship around the world. Entrepreneur Of The Year is the first and only truly global awards program of its kind. It celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. National Overall winners go on to compete for the EY World Entrepreneur Of The Year™ title. ey.com/us/eoy
About EY Private
As Advisors to the ambitious™, EY Private professionals possess the experience and passion to support private businesses and their owners in unlocking the full potential of their ambitions. EY Private teams offer distinct insights born from the long EY history of working with business owners and entrepreneurs. These teams support the full spectrum of private enterprises including private capital managers and investors and the portfolio businesses they fund, business owners, family businesses, family offices and entrepreneurs. Visit ey.com/us/private
About EY
EY exists to build a better working world, helping create long-term value for clients, people and society and build trust in the capital markets. Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate. Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.
Investor Inquiries:
Steven Cordovano
203-952-6373
scordovano@bioaegistx.com
Media Inquiries:
Christine Lagana
clagana@bioaegistx.com
This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.